BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 22, 2011
 |  BC Week In Review  |  Company News  |  Deals

Chugai, Roche deal

Roche granted its Chugai subsidiary exclusive rights to develop and commercialize vemurafenib in Japan. Roche is eligible for undisclosed milestones. Chugai plans to begin a Phase I trial to treat BRAF mutation-positive metastatic melanoma in Japan...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >